Lin BioScience (ROCO:6696) Cash-to-Debt : 111.68 (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lin BioScience's cash to debt ratio for the quarter that ended in Jun. 2024 was 111.68.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lin BioScience could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Lin BioScience's Cash-to-Debt or its related term are showing as below:

ROCO:6696' s Cash-to-Debt Range Over the Past 10 Years
Min: 14.67 Med: 211.92 Max: No Debt
Current: 111.68

During the past 8 years, Lin BioScience's highest Cash to Debt Ratio was No Debt. The lowest was 14.67. And the median was 211.92.

ROCO:6696's Cash-to-Debt is ranked better than
78.42% of 1483 companies
in the Biotechnology industry
Industry Median: 7.71 vs ROCO:6696: 111.68

Lin BioScience Cash-to-Debt Historical Data

The historical data trend for Lin BioScience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lin BioScience Cash-to-Debt Chart

Lin BioScience Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

14.67

211.92

360.04

35.38

76.06

Lin BioScience Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial											40.38	35.38	39.10	76.06	111.68

Competitive Comparison of Lin BioScience's Cash-to-Debt

For the Biotechnology subindustry, Lin BioScience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lin BioScience's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lin BioScience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lin BioScience's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Lin BioScience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lin BioScience's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3261.057	/	(13.847	+	29.026)
	=	76.06

Lin BioScience's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4165.62	/	(14.765	+	22.534)
	=	111.68

Lin BioScience (ROCO:6696) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lin BioScience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lin BioScience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110

Website

https://www.linbioscience.com

Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience Headlines

No Headlines